Inspirna

Inspirna

Biotechnology, 310 E 67th St, New York, 10065, United States, 11-50 Employees

rgenix.com

  • LinkedIn

phone no Phone Number: +16*********

Who is INSPIRNA

Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unm...

Read More

map
  • 310 E 67th St, New York, New York, 10065, United States Headquarters: 310 E 67th St, New York, New York, 10065, United States
  • 2010 Date Founded: 2010
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies
  • Usman Azam CEO:   Usman Azam

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INSPIRNA

Inspirna Org Chart and Mapping

Usman Azam

Chief Executive Officer

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Inspirna

Answer: Inspirna's headquarters are located at 310 E 67th St, New York, 10065, United States

Answer: Inspirna's phone number is +16*********

Answer: Inspirna's official website is https://rgenix.com

Answer: Inspirna's revenue is $10 Million to $25 Million

Answer: Inspirna's SIC: 2834

Answer: Inspirna's NAICS: 561110

Answer: Inspirna has 11-50 employees

Answer: Inspirna is in Biotechnology

Answer: Inspirna contact info: Phone number: +16********* Website: https://rgenix.com

Answer: Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirnas lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirnas second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in patients with advanced or metastatic lung cancer in combination with docetaxel and endometrial cancer in combination with ipilimumab through a clinical collaboration with Bristol Myers Squibb. Inspirna identifies novel cancer targets using its microRNA-based target discovery platform, RNA-DRIVEr, which was originally developed by Inspirnas scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access